Drug Resistance Mechanism and Therapeutic Strategy of Targeted Therapy of Non-small Cell Lung Cancer with MET Alterations
Mesenchymal to epithelial transition factor (MET) gene alterations involve in the proliferation, invasion, and metastasis of non-small cell lung cancer. MET-tyrosine kinase inhibitors (TKIs) have been approved to treat non-small cell lung cancer with MET alterations, and resistance to these TKIs is inevitable. Molecular mechanisms of resistance to MET-TKIs are completely unclear. The review focused on potential mechanisms of MET-TKIs resistance and therapeutics strategies to delay and prevent resistance.
DOI: 10.3779/j.issn.1009-3419.2023.102.33
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | China Health | Epithelial Cancer | Genetics | Lung Cancer | Non-Small Cell Lung Cancer